On the stock market since 2022, it operates in the world of health and science. It has 539 employees. Now — the numbers.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.11 per share each year — regular cash for whoever holds the stock.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
On our five-subject report card, JMDMF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JMDMF is a high-risk stock — not yet profitable, and its future rides on its product catching on.